Johnson & Johnson (NYSE: JNJ ) (NEOE: JNJ:CA ) started this year at the same price as it started 2020. Four years of no price appreciation is hardly an attractive proposition, even with a decent dividend. This article looks at why JNJ has stagnated, andMy approach is long-term and I focus on investing in macro ideas through low risk ETFs and CEFs. I have traded stocks and currencies for nearly ten years and currently run a family fund with my partner and fellow SA contributor Andrew McElroy. I also invest i ...

Johnson & Johnson (JNJ) closed at $146.18 in the latest trading session, marking a +1.75% move from the prior day. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.42%, while the tech-heavy Nasdaq depreciated by 1.89%. Heading into today, shares of the world's biggest maker of health care products had lost 3.97% over the past month, outpacing the Medical sector's loss of 6.22% and lagging the S&P 500's loss of 1.7% in that time. Investors will be eagerly watching ...

Johnson & Johnson (NYSE: JNJ ) is a one big enigma right now. And I like it. I’ve owned it since May and it has been a experience not unlike many I have had with other high quality dividend stocks. It isI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, ...

Median overall survival improvement expected to exceed one yearFirst and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancerRARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line therapy for p ...

J&J's Legal and Financial Challenges - J&J faces over 62,000 lawsuits related to its talc-based products, primarily baby powders, alleging asbestos contamination causing ovarian cancer [9] - The company failed twice in bankruptcy attempts to resolve talc lawsuits and proposed a $6.5 billion settlement over 25 years to resolve 99.75% of pending cases [2] - J&J's stock has underperformed the industry, falling 7.5% year-to-date compared to the industry's 3.1% growth [13] Patent Expiration and Market Impact - J&J's blockbuster drug Stelara, which generated $8.0 billion in sales in the first nine months of 2024, faces patent expiration in 2025 [3] - Biosimilars for Stelara are expected to launch in the US in January 2025, potentially eroding sales and profits [3] MedTech Segment Performance - J&J's MedTech segment faces headwinds in Asia Pacific, particularly in China, due to the volume-based procurement (VBP) program and anti-corruption campaign [11] - The company expects operational sales in the MedTech segment to grow 5% in 2024, near the lower end of its long-term target of 5%-7% [11] Innovative Medicine Unit Growth - J&J's Innovative Medicine unit is performing above market levels, with sales growth of 6.8% in 2022, 9% in 2023, and 5.6% in the first nine months of 2024 [12] - The company expects 10 new Innovative Medicine products, including cancer drugs Talvey and Tecvayli, to deliver peak non-risk-adjusted operational sales of $5 billion [5] Valuation and Stock Performance - J&J's stock is trading below its 200-day and 50-day moving averages and is cheaper than peers like Eli Lilly and Novo Nordisk [14] - The stock closed at $145.05, close to its 52-week low of $142.75, and has lost more than 10% in the past three months [19] Future Outlook and Strategic Moves - J&J expects positive growth in the Innovative Medicine segment in 2025 despite Stelara's patent expiration, with growth driven by key products like Darzalex and Tremfya [28] - The company has completed acquisitions in MedTech and Innovative Medicine, boosting its pipeline and expecting operational sales growth at the upper end of its 5-7% long-term target [27][28] Industry and Sector Trends - The drug and biotech sector experienced a downturn in the second half of the year due to disappointing Q3 sales, guidance cuts, pipeline setbacks, and political appointments [8] - J&J's stock underperformance is part of a broader trend affecting large drugmakers, influenced by sector-wide challenges [8]

Technical Analysis - JNJ stock's eight-day simple moving average of $144 97 is slightly below its current price, indicating a rare bullish signal [1] - JNJ stock has entered a bearish technical pattern known as the Death Cross, where the 50-day moving average falls below the 200-day moving average [3][6] - JNJ stock is currently priced at $145 58, below critical moving averages: 20-day ($144 97), 50-day ($154 24), and 200-day ($154 66), suggesting a firmly bearish trend [7] - The MACD is negative 2 72 and the Relative Strength Index is 36 84, further indicating a lack of confidence in the technical setup [7] Strategic Moves - The company is strategically focusing on differentiated mechanisms of action in dermatology [8] - Acquisitions in 2024 have bolstered the dermatology pipeline, emphasizing innovative treatments for atopic dermatitis (AD) and other immune-mediated conditions [8] - A licensing deal with Kaken Pharmaceutical for KP-723, a promising candidate targeting atopic dermatitis, is in place with plans to launch a phase I study in 2025 [11] Dividend and Financial Health - The company has ample liquidity, low leverage, and robust free cash flow, ensuring solid dividend sustainability despite bearish technical indicators [9] - Johnson & Johnson is a dividend aristocrat with over 60 years of consistent payouts, providing a safety net for investors [12] Long-Term Outlook - Despite the Death Cross casting a shadow over the short-term outlook, the company's commitment to growth, innovation, and reliable dividends underscores its long-term appeal [13] - The company is looking to tackle eczema and diversify its portfolio, indicating that the stock may be down but far from out [14]

Johnson & Johnson (JNJ)  announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD). The licensing deal for Kaken’s STAT6 program includes global rights to its lead candidate, KP-723.How the Licensing Deal for the AD Program Benefits JNJThe licensing deal with Kaken reinforces Johnson & Johnson’s dedication to targeting disease-specific pa ...

Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses. The best dividend stocks will send you more money each year by increasing their payments. Anybody can gift oneself with a multiyear supply of passive income by purchasing shares of a high-quality dividend-paying company. Three great ones to consider buying are Coca-Cola (KO -0.27%), Johnson & Johnson (JNJ 0.55%), and NextEra Ener ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $145.27, denoting a +0.55% adjustment from its last day's close. This change lagged the S&P 500's 0.73% gain on the day. Meanwhile, the Dow gained 0.16%, and the Nasdaq, a tech-heavy index, added 0.98%.Prior to today's trading, shares of the world's biggest maker of health care products had lost 6.9% over the past month. This has lagged the Medical sector's loss of 3.8% and the S&P 500's gain of 0.34% in that time.The investment community will ...

After massive rallies delivered by the growth part of my portfolio, it became imbalanced as the share of defensive plays decreased in relative terms. Therefore, I am adding Johnson & Johnson (NYSE: JNJ ) stock to my portfolio andAs an investor who started my path five years ago with my own capital, I represent a blend of hands on experience and academic background in corporate finance. Due to my relatively young age I thrive on discovering long-duration growth opportunities and actively seek out opportuniti ...